These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 18069108)
1. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals. Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108 [TBL] [Abstract][Full Text] [Related]
2. Conversion of C57Bl/6 mice from a tumor promotion-resistant to a -sensitive phenotype by enhanced ornithine decarboxylase expression. Guo Y; Zhao J; Sawicki J; Peralta Soler A; O'Brien TG Mol Carcinog; 1999 Sep; 26(1):32-6. PubMed ID: 10487519 [TBL] [Abstract][Full Text] [Related]
3. K6/ODC transgenic mice as a sensitive model for carcinogen identification. Chen Y; Megosh LC; Gilmour SK; Sawicki JA; O'Brien TG Toxicol Lett; 2000 Jul; 116(1-2):27-35. PubMed ID: 10906419 [TBL] [Abstract][Full Text] [Related]
4. Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Feith DJ; Shantz LM; Pegg AE Cancer Res; 2001 Aug; 61(16):6073-81. PubMed ID: 11507056 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Lan L; Trempus C; Gilmour SK Cancer Res; 2000 Oct; 60(20):5696-703. PubMed ID: 11059762 [TBL] [Abstract][Full Text] [Related]
6. Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Smith MK; Trempus CS; Gilmour SK Carcinogenesis; 1998 Aug; 19(8):1409-15. PubMed ID: 9744537 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components. Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758 [TBL] [Abstract][Full Text] [Related]
14. Mouse skin chemical carcinogenesis is inhibited by antizyme in promotion-sensitive and promotion-resistant genetic backgrounds. Feith DJ; Shantz LM; Shoop PL; Keefer KA; Prakashagowda C; Pegg AE Mol Carcinog; 2007 Jun; 46(6):453-65. PubMed ID: 17219416 [TBL] [Abstract][Full Text] [Related]
15. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Arbeit JM; Riley RR; Huey B; Porter C; Kelloff G; Lubet R; Ward JM; Pinkel D Cancer Res; 1999 Aug; 59(15):3610-20. PubMed ID: 10446971 [TBL] [Abstract][Full Text] [Related]
16. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. O'Brien TG; Megosh LC; Gilliard G; Soler AP Cancer Res; 1997 Jul; 57(13):2630-7. PubMed ID: 9205069 [TBL] [Abstract][Full Text] [Related]
17. Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model. Umemura T; Kodama Y; Nishikawa A; Hioki K; Nomura T; Kanki K; Kuroiwa Y; Ishii Y; Kurokawa Y; Hirose M Cancer Lett; 2006 Jan; 231(2):314-8. PubMed ID: 16399233 [TBL] [Abstract][Full Text] [Related]
18. Chemopreventive effect of farnesol on DMBA/TPA-induced skin tumorigenesis: involvement of inflammation, Ras-ERK pathway and apoptosis. Chaudhary SC; Alam MS; Siddiqui MS; Athar M Life Sci; 2009 Jul; 85(5-6):196-205. PubMed ID: 19470390 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II. Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852 [TBL] [Abstract][Full Text] [Related]
20. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development. Storer RD; Sistare FD; Reddy MV; DeGeorge JJ Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]